Review of olaparib for ovarian cancer

Share :
Published: 25 Jul 2016
Views: 2557
Rating:
Save
Dr Michel Vulfovich - Memorial Cancer Institute, Hollywood, Florida, USA

 Dr Vulfovich speaks with ecancertv at the Best of ASCO 2016 about novel treatments for ovarian cancer.

Using BRCA mutations as a marker, he describes the significance of PARP inhibitor treatment on survival.

For the initial announcement of results from olaparib in ovarian cancer, you can watch an interview with Dr Jonathan Ledermann here.